脑膜瘤相关:一个快乐的结局?
Giada Pauletto1, Annacarmen Nilo2, Sara Pez3
1Neurology Unit, Head-Neck and Neurosciences Department, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy.
Journal of personalized medicine
|July 29, 2023
概括
在脑膜瘤中,发作很常见,通常在发病时就出现. 脑膜瘤的手术可以导致的积极结果,没有观察到与疾病进展的联系.
科学领域:
- 神经外科 神经外科
- 神经学 神经学
- 在瘤学瘤学.
背景情况:
- 发作影响了三分之一以上的脑膜瘤患者,通常是最初的症状.
- 手术后持续性发生在高达30%的病例中.
- 了解手术前发作预测因素对于患者管理至关重要.
研究的目的:
- 在新诊断的脑膜瘤患者中确定与手术前发作相关的危险因素.
- 评估脑膜瘤相关的术后结果.
主要方法:
- 对358名因新诊断的大脑脑膜瘤而接受手术的患者进行了回顾性分析.
- 确定和比较患有和没有手术前的患者之间的危险因素.
主要成果:
- 确定了主要的发作风险因素:患者年龄,周围胀和瘤位置.
- 发作患者年轻,卡诺夫斯基性能状态 (KPS) 较低,以及更多的手术前胀.
- 瘤位于凸度和较低的辛普森等级与发作有关.
- 在24个月后,88.2%的患者实现了优异的控制 (英格尔Ia级).
结论:
- 脑膜瘤相关的通常在手术干预后显示出有利的结果.
- 脑膜瘤手术后的似乎与疾病进展无关.
- 需要进一步的研究,以充分阐明长期影响.
相关概念视频
Arteries of the Lower Limbs
214
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
214
Seizures: Classification
419
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
419
Antiepileptic Drugs: GABAergic Pathway Potentiators
461
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
461
Antiepileptic Drugs: Glutamate Antagonists
422
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
422
Antiepileptic Drugs: Potassium Channel Activators
214
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
214
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346


